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Introduction
Sentinel lymph node biopsy (SLNB) is a minimally inva-
sive technique, performed in conjunction with radiotracer
injection and lymphoscintigraphy. This allows the surgeon
to identify and excise targeted upper echelon lymph nodes
that drain the site of a primary malignancy for the labora-
tory detection of what would otherwise be subclinical nodal
metastases. This technique oVers a less invasive means of
staging lymphatic basins in a patient with a primary malig-
nancy, and permits detailed histological, immunohisto-
chemical, and molecular examination of at least the Wrst
echelon (frequently second and rarely third) lymph node
basin for clinically occult micro- and conventional metasta-
ses (clinical stage N0). Use of this technique may poten-
tially avoid overtreatment of patients with oral or
oropharyngeal squamous cell carcinoma who undergo elec-
tive or opportune neck dissection and are subsequently
declared pathologically N0, and hence reduce neck dissec-
tion-associated morbidity [1].
The sentinel node concept was Wrst described by
Cabanas [2] in 1977 for squamous cell carcinoma of the
penis. In 1992, Morton et al. [3] reintroduced the concept of
surgical sentinel lymph node sampling. Their landmark
publication described their early prospective clinical expe-
rience with SLNB using blue dye in patients with clinically
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node-negative cutaneous malignant melanoma. The crucial
introduction of radionuclides as the injected tracer can be
attributed to Alex and Krag [4], who devised the current
method involving nuclear imaging and a handheld gamma
probe to identify sentinel lymph nodes, the technique that
has become the standard of care for cutaneous malignant
melanoma.
Oral squamous cell carcinoma (OSCC), like melanoma,
is characterized by an anatomically stepwise progression of
regional lymphatic metastases, and there has been an inter-
est in the application of the technique to this disease. For-
mal lymphadenectomy of the draining lymphatic basins is a
traditional option in OSCC. However, the current standard
approach—selective neck dissection for deeply invasive
lesions and “watchful waiting only” for superWcial
lesions—remains controversial. As increasing numbers of
centers consider applying SLNB to OSCC patients, multi-
ple other issues and questions arise regarding appropriate
training and experience, patient selection, surgical and
pathological techniques, and patient follow-up.
Controversies in the management of the N0 lymphatic 
basin for OSCC
Patients with OSCC are usually examined by computed
tomography (CT), magnetic resonance imaging (MRI), ultra-
sound-guided  Wne needle aspiration biopsy (USFNAB) or
more recently positron emission tomography (PET) for eval-
uation of neck status, all of which have signiWcant false-neg-
ative and false-positive rates. For detection of suspicious
nodes appreciated on physical examination, USFNAB has
proven to be the most accurate of these techniques [5],
although the method is labor-intensive and operator depen-
dent [6]. Nevertheless, these imaging techniques are not
invariably capable of detecting nodal metastases.
Observation after removal of the primary tumor, “watch-
ful waiting”, with neck dissection only if clinical cervical
metastases develop, has been proposed for patients with
primary lesions considered at low risk for lymphatic metas-
tases, based on small size (less than 2 cm), minimal depth
of invasion (for example less than 4 mm in primary tumors
of the oral tongue), and favorable histological diVerentia-
tion [7, 8]. In these patients, close watching of the neck dur-
ing follow-up has been recommended [9]. Depth of
invasion has become the most widely accepted parameter
for selecting patients for safe observation. However, a
recent evaluation of a large population of patients with oral
cancer who underwent SLNB found that tumor thickness
was not a statistically signiWcant predictor of positive senti-
nel nodes, whereas tumor diVerentiation, lymphovascular
invasion, and invasive growth patterns were predictive
[10]. This study was more robust than previous studies on
this subject, as the true status of the neck was more accu-
rately determined by step-serial sectioning and immunohis-
tochemistry of the sentinel node. This study calls into
question the widespread use of depth of invasion over all
other variables as the primary means of allocating patients
to “watchful waiting” versus neck dissection. In general,
the presence of favorable histopathological characteristics
in the primary tumor may indicate reduced risk, but does
not negate the risk of metastases. Hence, no reliable tools
are currently available that consistently achieve a high pre-
dictive value for occult metastasis.
Although there are no universally accepted guidelines,
the predominant opinion is that a patient with a clinically
N0 neck should have a neck dissection, if the risk of occult
metastasis is more than approximately 15–20% [11–15].
This approach is supported primarily by retrospective stud-
ies that have demonstrated that a concomitant neck dissec-
tion is associated with a decreased rate of regional
recurrence and distant metastases [15,  16]. Furthermore,
one randomized study showed that patients with OSCC and
a clinically N0 neck, who did not have concomitant neck
dissections, often presented later with neck metastases and
incurable disease. Salvage surgery was successful in only
24% of these patients. However, patients with a prophylac-
tic neck dissection had a reduction of recurrence in the neck
alone, from 33 to 12% [17]. It should be kept in mind that
the stage at which recurrences are detected is also depen-
dent on the means and intensity of follow-up and may well
determine the salvage rates. In addition, pathologic studies
have shown that even small lymph node metastases, which
are neither palpable nor obvious on imaging studies, can
have extracapsular extension, including lymphovascular
and perineural invasion, and other poor prognostic indica-
tors [18–21]. Visualization and palpation of lymph nodes
intraoperatively are unreliable predictors of nodal metasta-
ses by themselves [21]. In centers experienced in this pro-
cedure, USFNAB for follow-up enables early detection of a
signiWcant percentage of neck failures and a high salvage
rate with therapeutic neck dissection [22]. However, this
strategy may result in more extensive salvage surgeries for
gross cervical metastases and more frequent postoperative
radiotherapy, as compared to an approach that addresses the
cervical lymphatics in conjunction with the initial surgical
treatment.
The evaluation and treatment of lymphatic metastasis is
further confounded by evidence that traditional surgical
procedures, while accurate for the majority of patients, may
miss involved lymph nodes in patients with variations in
lymphatic anatomy or due to limitations in our ability to
identify isolated tumor cells and micrometastases using tra-
ditional histopathologic techniques, where identifying min-
imal disease can be like Wnding the proverbial “needle in a
haystack” [23].Eur Arch Otorhinolaryngol (2010) 267:839–844 841
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In summary, for OSCC, the probability of microscopic
involvement of lymph nodes than can be estimated based
on clinical Wndings and routine histopathology is at best an
approximation. For oral cavity malignancies, the reported
20–40% risk of occult metastases must be weighed against
the morbidity of dissecting the majority of necks that are
not truly involved. The need for a better diagnostic tech-
nique to identify subclinical cervical metastases and guide
the treatment of these patients ultimately has lead to the
development of SLNB. Another development reducing the
probability of occult metastasis and facilitating more ade-
quate treatment decisions may be the availability of biolog-
ical tests performed on the primary tumor specimen, but the
promising early results of such proWles need to be validated
[24]. The decision to observe a patient at moderate risk for
lymphatic metastases who has a clinically negative neck,
which was sensible in the era of more radical neck proce-
dures, is made more diYcult with the current practice
favoring selective, functional neck dissections, and might
become even less common if the evidence base for SLNB
becomes stronger.
SLNB for OSCC
Between 1996 and 2000, multiple centers initiated single
institutional trials studying SLNB for OSCC [25–29]. More
than 60 single institution trials, two international confer-
ence consensus documents, a meta-analysis, and recent
joint practice guidelines have since been published con-
cerning this topic [30–32]. A large multi-institutional path-
ologic validation trial has supported previous pathologic
validation trials and established that the sentinel node con-
cept applies to OSCC as it does to cutaneous melanoma and
breast cancer. The pathologic status of the sentinel node
correlated well with the status of subsequent immediate for-
mal lymphadenectomy [33]. Several large prospective clin-
ical observational trials on SLNB in OSCC, with selective
neck dissection reserved only for proven positive lymphatic
metastases, have been conducted to date [34, 35]. Three
prospective studies of SLNB as primary neck management
for stage I and II oral cavity cancer [Sentinel Node Euro-
pean Trial (SENT), the Danish National Group Trial
(DAHANCA 22), and the Brazilian Head and Neck Group]
are in progress.
The consensus in the literature regarding this topic is
that: (1) the predictive value of a negative sentinel lymph
node varies between 90 and 100%; (2) step-serial section-
ing and immunohistochemistry is essential in proper evalu-
ation of the sentinel lymph node; (3) this use of step-serial
sectioning and immunohistochemistry can signiWcantly
improve the negative predictive value of this technique; (4)
signiWcant upstaging of the lymphatic basins occurs with
this technique relative to standard formal lymphadenec-
tomy; (5) unexpected patterns of lymphatic drainage can
indeed occur, including unanticipated contralateral drain-
age to nodes that might be missed with standard lympha-
denectomies, and (6) if immediate assessment of lymph
nodes using frozen section, imprint cytology or molecular
biological techniques reliably show a sentinel lymph node
metastasis, a neck dissection can be performed at the same
sitting. Nevertheless, signiWcant concerns exist regarding
the need for staged surgery in the small percentage of
patients whose sentinel nodes are found to be positive at a
later date (after formal processing including immunohisto-
chemistry, which typically adds 1–2 days to the preparation
of the Wnal pathology report), as well as with regard to the
risk of false-negatives in what would otherwise be a highly
curable condition. The optimum management of the neck
that harbors only a single micrometastasis or even isolated
tumor cells is, as yet, uncertain. Some have conjectured that
removal of just the sentinel node may be suYcient in these
patients, though this has not been formally studied.
Morbidity of SLNB versus selective neck dissection
Selective neck dissection was developed primarily as a
means of reducing the morbidity related to more radical
approaches to the neck. However, signiWcant morbidity
remains even with the selective procedure, including adhe-
sive capsulitis of the shoulder (which can occur even after
only transient weakness of the trapezius muscle), lip move-
ment asymmetry, and contour changes in the neck. This has
been documented in multiple quality of life studies and
functional assessments [36–39]. In theory, an inexperi-
enced operator could create more injury through a narrow
exposure approach to the neck than a formal dissection.
However, several studies have documented negligible mor-
bidity with SLNB in the hands of experienced head and
neck surgeons [40]. No contour changes occur, and capsu-
lar dissection of lymph nodes minimizes the need for nerve
dissection. For patients with minimal disease detected after
Wnal pathological analysis, the option of early re-explora-
tion allows for completion neck dissection without
increased morbidity. In a recent study, Murer et al. [41]
compared complication rate, morbidity, and postoperative
shoulder function in a large cohort undergoing either SLNB
or elective neck dissection. Subjective impairment was
assessed with the neck dissection impairment index (NDII)
questionnaire. The functional status was evaluated by the
assessment of shoulder function with the modiWed individ-
ual relative Constant score. Perhaps not surprisingly, SLNB
was associated with signiWcantly fewer complications, less
subjective neck and shoulder impairment, and better objec-
tive shoulder function than elective neck dissection. SLNB842 Eur Arch Otorhinolaryngol (2010) 267:839–844
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has recently been shown to be associated with better quality
of life compared to selective neck dissection [42].
Apart from the eventual functional and oncological out-
comes, the morbidity and costs involved in the several
strategies for treatment of the N0 neck should be factored in
before arriving at more deWnitive answers.
Discussion
The sentinel lymph node procedure has become a well
investigated and elaborated technique and much has
already been accomplished. However, some issues still
need further development. An important issue to be
resolved before SLNB can be advocated more strongly for
the majority of deeply invasive oral cancers is our limited
ability to achieve immediate diagnosis of positive sentinel
nodes. The use of frozen section is controversial as tissue
that has been frozen, then thawed, and then processed for
routine light microscopic examination may be compro-
mised by this handling, and might not represent the true sta-
tus of the entire specimen. Although some groups do
advocate frozen section for immediate conversion to selec-
tive neck dissection, with reduction in the need for reopera-
tion [35, 43, 44], this is still a matter of debate.
To be clear, there are several inherent potential pitfalls to
be aware of, when selecting a deWnitive method of triaging
patients for further treatment: Wrst, there is evidence that
skip metastases—i.e., metastases that skip over the Wrst
echelon draining node to lodge in nodes further down-
stream—do exist, which means that sampling sentinel
nodes alone can yield false-negative results in those infre-
quent patients with skip metastases [45]. Therefore, guide-
lines to deWne which second echelon “sentinel” nodes have
to be harvested are needed. Such guidelines are not incor-
porated in the joint practice guidelines [1], and multiple
algorithms exist. Second, routine light microscopy, whether
at the time of surgery (frozen section examination) or after
Wxation, runs a risk of overlooking tiny metastatic deposits.
Light microscopic examination is, in essence, a sampling
process, which means that tiny deposits made up of a lim-
ited number of tumor cells may be left behind in the tissue
not sampled (or even in the portion of the tissue block not
actually cut) [46]. This may be improved by step-serial sec-
tioning but cannot entirely be circumvented. Finally, soft
tissue tumor deposits (i.e., tumor deposits which are not
clearly associated with an encompassing lymph node) may
be encountered in neck dissection specimens, and would
not be identiWed by sentinel node sampling procedures [47].
For the patient with a microscopic metastatic deposit in
the sentinel node, not detected at the initial SLNB, we are
dealing with issues that potentially include re-exploration
and dissection of functionally important nerves in a
recently operated wound. If the Wnal pathology report can
be made available to permit the patient to be taken back to
surgery within 7 days, the concern is lessened, but a timely
pathology report can be logistically challenging in some
centers. Ultimately, rapid reverse transcriptase-polymerase
chain reaction assessment of nodes may provide immediate
information regarding the status of the sentinel node, but
this technique has not yet been validated for clinical use
[48].
As selective neck dissection has traditionally been advo-
cated if the risk of subclinical metastases exceeds 15–20%
[11–15], we are applying “watchful waiting” to a group of
patients who still have signiWcant risk, including many lip
lesions, thin T1 cancers in other areas of the oral cavity, and
other lesions with low probability of metastasis. For an
increasing number of head and neck surgeons, SLNB is con-
sidered a reasonable option for patients with low but not
negligible risk of harboring lymphatic metastases, and selec-
tive neck dissection remains the mainstay for patients with
higher risk of subclinical nodal involvement. However, as
discussed earlier, the appropriate population for SLNB, with
an intermediate risk of occult metastasis, needs to be deWned
more clearly, and tools for risk assessment are currently rel-
atively limited. An alternative approach is to oVer SLNB to
all patients with OSCC. However, if the neck has to be
entered for primary tumor resection or free Xap reconstruc-
tion in larger tumors, it may be more rational to perform a
selective or opportune neck dissection in these cases.
Multiple authors have emphasized the signiWcant learn-
ing curve that exists for SLNB. In the American College of
Surgeons Oncology Group pathologic validation trial, there
was a statistically signiWcant diVerence in the negative pre-
dictive value of SLNB between experienced surgeons and
beginning surgeons, even though the latter had performed
Wve cases and participated in an animal laboratory [33]. It is
important for surgeons to receive initial instruction in the
proper handling of the gamma probe. The surgeon should
subsequently gain experience in the use of the gamma
probe by performing SLNB prior to a planned completion
neck dissection. This can be performed in a “gamma probe-
guided neck dissection”, in which the sentinel node is
examined more meticulously using step-serial sectioning
and immunohistochemistry to obtain a more reliable histo-
pathological examination. This procedure oVers beneWts to
the patient, and is more than just a means of gaining experi-
ence. SigniWcant upstaging of the cervical nodes can be
anticipated by virtue of the gamma probe-assisted proce-
dure [23, 39]. Clearly these patients can be more intelli-
gently followed and treated when we understand the true
status of the neck. Thus, SLNB in the context of a comple-
tion selective neck dissection oVers the opportunity for
more accurate staging of minimal, but signiWcant, neck dis-
ease, and can be oVered to patients in good conscience.Eur Arch Otorhinolaryngol (2010) 267:839–844 843
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Equally important is the occasional unpredictability of
lymphatic pathways, which is well recognized for cutane-
ous lesions, and also occurs with oral lesions. In fact for
lesions not involving the midline but within a few centi-
meters of it, gamma probe-guided surgery may provide a
superior solution for these patients in whom we often
struggle with decisions regarding contralateral neck
management.
The SLNB remains an exciting area of development for
OSCC and other head and neck mucosal lesions. Technolo-
gies are rapidly improving, and surgeons are becoming
more experienced. It is very likely that the use of SLNB
will increase as technological reWnements [e.g. single pho-
ton emission CT and CT (SPECT/CT), intraoperative
gamma camera and Xuorescence imaging] occur, and that it
will be applied in an increasingly wider group of mucosal
lesions.
Conclusions
The technique of SLNB oVers the potential for more ana-
tomically accurate surgery based on each patient’s unique
lymphatic drainage pattern. It has been demonstrated to
have an excellent safety proWle with good sensitivity in
identifying occult neck metastases. Use of this technique
can potentially allow selection of patients for selective neck
dissection, sparing them the morbidity of overtreatment and
oVer better quality of life. Selective neck dissection has
only a 5% chance of not securing control of neck metasta-
ses, and it may well transpire on longitudinal studies that
SLNB has similar oncologic eYcacy. However, in the
absence of reproducible level-1 evidence and the existence
of a deWned learning curve, centers commencing SLNB
should oVer this procedure within a trial setting, and the
results should be closely monitored. In centers with ade-
quate experience, SLNB can be oVered to appropriate
patients with nodal negative T1 and T2 OSCC for accurate
histopathologic staging of the neck, with periodic audit of
oncologic outcomes.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Alkureishi LW, Burak Z, Alvarez JA et al (2009) Joint practice
guidelines for radionuclide lymphoscintigraphy for sentinel node
localization in oral/oropharyngeal squamous cell carcinoma. Ann
Surg Oncol 16:3190–3210
2. Cabanas RM (1977) An approach for the treatment of penile car-
cinoma. Cancer 39:456–466
3. Morton DL, Wen D-R, Wong JH et al (1992) Technical details of
intraoperative lymphatic mapping for early stage melanoma. Arch
Surg 127:392–399
4. Alex JC, Krag DN (1996) The gamma-probe-guided resection of
radiolabeled primary lymph nodes. Surg Oncol Clin N Am 5:33–
41
5. de Bondt RB, Nelemans PJ, Hofman PA et al (2007) Detection of
lymph node metastases in head and neck cancer: a meta-analysis
comparing US, USgFNAC, CT and MR imaging. Eur J Radiol
64:266–272
6. Takes RP, Knegt PPM, Manni JJ et al (1996) Regional metastasis
in head and neck squamous cell cancer: the value of ultrasound
with UGFNAB revised. Radiology 198:819–823
7. Shear M, Hawkins DM, Farr HW (1976) The prediction of lymph
node metastases from oral squamous carcinoma. Cancer 37:1901–
1907
8. Martínez-Gimeno C, Rodríguez EM, Vila CN, Varela CL (1995)
Squamous cell carcinoma of the oral cavity: a clinicopathologic
scoring system for evaluating risk of cervical lymph node metas-
tasis. Laryngoscope 105:728–733
9. Pillsbury HC, Clark M (1997) A rationale for therapy of the N0
neck. Laryngoscope 107:1294–1315
10. Goerkem M, Braun J, Stoeckli SJ (2010) Evaluation of clinical and
histomorphological parameters as potential predictors of occult
metastases in sentinel lymph nodes of early squamous cell carci-
noma of the oral cavity. Ann Surg Oncol 17:527–535
11. Pitman KT, Johnson JT, Myers EN (1997) EVectiveness of the
selective neck dissection for the management of the clinically neg-
ative neck. Arch Otolaryngol Head Neck Surg 123:917–922
12. McGuirt WF Jr, Johnson JT, Myers EN, RothWeld R, Wagner R
(1995) Floor of mouth carcinoma. The management of the clini-
cally negative neck. Arch Otolaryngol Head Neck Surg 121:278–
282
13. Shingaki S, Kobayashi T, Suzuki I, Kohno M, Nakajima T (1995)
Surgical treatment of stage I and II oral squamous cell carcinomas:
analysis of causes of failure. Br J Oral Maxillofac Surg 33:304–
308
14. Shah JP, Andersen PE (1995) Evolving role of modiWcations in
neck dissection for oral squamous carcinoma. Br J Oral Maxillofac
Surg 33:3–8
15. Clayman GL, Frank DK (1998) Selective neck dissection of ana-
tomically appropriate levels is as eYcacious as modiWed radical
neck dissection for elective treatment of the clinically negative
neck in patients with squamous cell carcinoma of the upper respi-
ratory and digestive tracts. Arch Otolaryngol Head Neck Surg
124:348–352
16. Yuen APW, Wei WI, Wong YM, Tang KC (1997) Elective neck
dissection versus observation in the treatment of early oral tongue
carcinoma. Head Neck 19:583–588
17. Kligerman J, Lima RA, Soares JR et al (1994) Supraomohyoid
neck dissection in the treatment of T1/T2 squamous cell carcinoma
of oral cavity. Am J Surg 168:391–394
18. Braams JW, Pruim J, Freling NJM et al (1995) Detection of lymph
node metastases of squamous-cell cancer of the head and neck
with FDG-PET and MRI. J Nucl Med 36:211–216
19. Alvi A, Johnson JT (1996) Extracapsular spread in the clinically
negative neck (N0): implications outcome. Otolaryngol Head
Neck Surg 114:65–70
20. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq
J (1994) Lymph node prognostic factors in head and neck squa-
mous cell carcinomas. Am J Surg 168:494–498
21. Rassekh CH, Johnson JT, Myers EN (1995) Accuracy of intraop-
erative staging of the N0 neck in squamous cell carcinoma. Laryn-
goscope 105:1334–1336
22. Nieuwenhuis EJ, Castelijns JA, Pijpers R et al (2002) Wait-and-
see policy for the N0 neck in early-stage oral and oropharyngeal844 Eur Arch Otorhinolaryngol (2010) 267:839–844
123
squamous cell carcinoma using ultrasonography-guided cytology:
is there a role for identiWcation of the sentinel node? Head Neck
24:282–289
23. Ross GL, Shoaib T, Soutar DS et al (2002) The use of sentinel
node biopsy to upstage the clinically N0 neck in head and neck
cancer. Arch Otolaryngol Head Neck Surg 128:1287–1290
24. Roepman P, Wessels LF, Kettelarij N et al (2005) An expression
proWle for diagnosis of lymph node metastases from primary head
and neck squamous cell carcinomas. Nat Genet 37:182–186
25. Shoaib T, Soutar DS, MacDonald DG et al (2001) The accuracy of
head and neck carcinoma sentinel lymph node biopsy in the clini-
cally N0 neck. Cancer 91:2077–2083
26. Civantos FJ, Gomez C, Duque C et al (2003) Sentinel node biopsy
in oral cavity cancer: correlation with PET scan and immunohisto-
chemistry. Head Neck 25:1–9
27. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S (2001) Sentinel lymph
node evaluation in squamous cell carcinoma of the head and neck.
Otolaryngol Head Neck Surg 125:221–226
28. Zitsch RP III, Todd DW, Renner GJ, Singh A (2000) Intraopera-
tive radiolymphoscintigraphy for detection of occult nodal metas-
tasis in patients with head and neck squamous cell carcinoma.
Otolaryngol Head Neck Surg 122:662–666
29. Taylor RJ, Wahl RL, Sharma PK et al (2001) Sentinel node local-
ization in oral cavity and oropharynx squamous cell cancer. Arch
Otolaryngol Head Neck Surg 127:970–974
30. Stoeckli SJ, Alkureishi LW, Ross GL (2009) Sentinel node biopsy
for early oral and oropharyngeal squamous cell carcinoma. Eur
Arch Otorhinolaryngol 266:787–793
31. Stoeckli SJ, Pfaltz M, Ross GL et al (2005) The second interna-
tional conference on sentinel node biopsy in mucosal head and
neck cancer. Ann Surg Oncol 12:919–924
32. Paleri V, Rees G, Arullendran P, Shoaib T, Krishman S (2005)
Sentinel node biopsy in squamous cell cancer of the oral cavity and
oral pharynx: a diagnostic meta-analysis. Head Neck 27:739–747
33. Civantos FJ, Zitsch RP, Schuller DE et al (2010) Sentinel lymph
node biopsy accurately stages the regional lymph nodes for T1-T2
oral squamous cell carcinomas: results of a prospective multi-
institutional trial. J Clin Oncol [Epub ahead of print]
34. Ross GL, Soutar DS, MacDonald DG et al (2004) Sentinel node
biopsy in head and neck cancer: preliminary results of a multicen-
ter trial. Ann Surg Oncol 11:690–696
35. Stoeckli SJ (2007) Sentinel node biopsy for oral and oropharyn-
geal squamous cell carcinoma of the head and neck. Laryngoscope
117:1539–1551
36. Chepeha DB, Taylor RJ, Chepeha JC et al (2002) Functional
assessment using Constant’s Shoulder Scale after modiWed radical
and selective neck dissection. Head Neck 24:432–436
37. Kuntz AL, Weymuller EA Jr (1999) Impact of neck dissection on
quality of life. Laryngoscope 109:1334–1338
38. Rogers SN, Ferlito A, Pellitteri PK, Shaha AR, Rinaldo A (2004)
Quality of life following neck dissections. Acta Otolaryngol
124:231–236
39. van Wilgen CP, Dijkstra PU, Nauta JM, Vermey A, Roodenburg
JL (2003) Shoulder pain and disability in daily life, following su-
praomohyoid neck dissection: a pilot study. J Craniomaxillofac
Surg 31:183–186
40. Civantos FJ, MoVat FL, Goodwin WJ (2006) Lymphatic mapping
and sentinel lymphadenectomy for 106 head and neck lesions:
contrasts between oral cavity and cutaneous malignancy. Laryngo-
scope 112(Suppl 109):1–15
41. Murer K, Huber G, Haile SR, Stoeckli SJ (2010) Comparison of
morbidity between sentinel node biopsy and elective neck dissec-
tion for treatment of the N0 neck in patients with oral squamous
cell carcinoma. Head Neck (in press)
42. Schiefke F, Akdemir M, Weber A et al (2009) Function, postoper-
ative morbidity, and quality of life after cervical sentinel node bi-
opsy and after selective neck dissection. Head Neck 31:503–512
43. Terada A, Hasegawa Y, Yatabe Y et al (2008) Intraoperative diag-
nosis of cancer metastasis in sentinel lymph node of oral cancer
patients. Oral Oncol 44:838–843
44. Tschopp L, Nuyens M, StauVer E, Krause T, Zbären P (2005) The
value of frozen section analysis of the sentinel lymph node in clin-
ically N0 squamous cell carcinoma of the oral cavity and orophar-
ynx. Otolaryngol Head Neck Surg 132:99–102
45. Ferlito A, Shaha AR, Rinaldo A, Pelliteri PK, Mondin V, Byers
RM (2002) “Skip metastases” from head and neck cancers. Acta
Otolaryngol 122:788–791
46. Ferlito A, Rinaldo A (2000) Controversies in the treatment of N0
neck in laryngeal cancer: neck dissection, no surgery or sentinel
lymph node biopsy? ORL J Otorhinolaryngol Relat Spec 62:287–
289
47. Jose J, Ferlito A, Rodrigo JP, Devaney KO, Rinaldo A, MacLen-
nan K (2007) Soft tissue deposits from head and neck cancer: an
under-recognised prognostic factor? J Laryngol Otol 121:1115–
1117
48. Ferris RL, Xi L, Raja S et al (2005) Molecular staging of cervical
lymph nodes in squamous cell carcinoma of the head and neck.
Cancer Res 65:2147–2156